<DOC>
	<DOCNO>NCT00280878</DOCNO>
	<brief_summary>This Phase II pilot study evaluate safety risk-adjusted outpatient-based approach lymphoma salvage therapy VGF ( vinorelbine , gemcitabine pegfilgrastim ) and/or F-GIV ( gemcitabine , Ifosfamide , vinorelbine pegfilgrastim ) combination Rituximab ( R-VGF/R-F-GIV ) .</brief_summary>
	<brief_title>Rituximab Combination With Outpatient Therapy CD20+ Lymphoma</brief_title>
	<detailed_description>Recent epidemiologic survey demonstrate dramatic increase incidence non-Hodgkin 's lymphoma ( NHL ) . NHL one rapidly increase malignancy industrial world . The purpose project evaluate efficacy safety outpatient treatment relapse treatment resistant ( refractory ) CD20+ lymphoma . Two combination chemotherapy drug test depend patient prior therapy response - rituximab , vinorelbine gemcitabine ( R-VGF ) OR rituximab , vinorelbine , gemcitabine ifosfamide ( R-FGIV ) . Previous experience , include recently complete study use combination vinorelbine , gemcitabine ifosfamide demonstrate outpatient approach safe similar efficacy presently available alternative inpatient chemotherapy approach . This study expand finding previous study add rituximab . Rituximab increasingly successfully use therapy CD20+ NHL . It specific protein ( antibody ) direct surface protein ( CD20 antigen ) find CD20+ lymphoma cell therefore lead destruction cell . Rituximab also highly favourable toxicity profile enable outpatient treatment . All factor provide strong rationale combination rituximab novel outpatient-based salvage approach VGF F-GIV recently evaluate . This pilot study 12 patient test feasibility combination approach patient relapsed/refractory CD20+ NHL .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>Age &gt; 18 year Relapsed primary refractory CD20+ NHL ECOG 0 2 Written inform consent Intention proceed form transplant therapy follow few 2 cycle protocol salvage therapy . Bilirubin &gt; 50Âµmol/litre unless secondary lymphoma Creatinine &gt; 2 x upper limit normal unless secondary lymphoma Absolute neutrophil count &lt; 0.5 x 109/litre / platelet &lt; 50 x 109/litre unless secondary lymphoma Relapse within 6 month prior transplant procedure ( autologous allogeneic ) . Known sensitivity E coli derive preparation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>CD20+</keyword>
</DOC>